Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Exelixis
Biotech
Exelixis drops ADC after deciding it's no match for Tivdak
Exelixis is giving up on its tissue factor-targeting ADC after concluding the candidate was unlikely to best Pfizer and Genmab’s Tivdak.
James Waldron
Aug 7, 2024 5:22am
Exelixis lays off 175 employees in refocus on emerging pipeline
Jan 8, 2024 6:10am
Exelixis dips into the AI game, LIB cashes in on PCSK9
Sep 12, 2023 11:00am
Leaps by Bayer chief jumps to Bayer, too—Chutes & Ladders
Aug 25, 2023 9:30am
Eikon builds out clinical development team—Chutes & Ladders
Jun 2, 2023 9:30am
Ex-Rubius CEO goes to Incyte—Chutes & Ladders
May 12, 2023 9:30am
